Xxxxxxxx, A. T., Xxxxxxx, A.M., Xxxxxxx, N., Xxxx, P.U., Nanoparticles as carriers for oral peptide absorption studies in particle uptake and fate. J. Control. Release. 1995, 36: 39-46.
Xxxxxxxx, A. A. Franchising and franchise agreement: results and prospects of legal
Xxxxxxxx, A. If syndromic surveillance is the answer, what is the question? Biosecurity & Bioterrorism. 2015;1(2):77-81.
Xxxxxxxx, A. L. J. Am. Chem. Soc. 2004, 126, 15883-15889.
Xxxxxxxx, A. L.; Xxxxxxxxxx, M. E. Langmuir 2005, 21, 9010-9012.
Xxxxxxxx, A. L.; Xxxxxx, X. X. Langmuir 2007, 23, 11434- 11442.
Xxxxxxxx, A. S., Xxx, F., Xxx, X., Xxxxxxxx, S., Xx, P., XxxXxxx, W., . . . Xxxxx, X. (2012). Second-hand smoke exposure and household smoking bans in Chinese families: a qualitative study. [Research Support, Non-U.S. Gov't]. Health Soc Care Community, 20(4), 356-364. doi: 10.1111/j.1365- 2524.2011.01035.x 44. Xxxx, X. X., & Xxxxxx, X. X. (1984). The health belief model: A decade later.
Xxxxxxxx, A. I. et al. The spin chirality in MnSi single crystal probed by small angle scattering with polarized neutrons. Physica B 350, e323–e326 (2004).
Xxxxxxxx, A n.; Xxxxxxxx, V.;
Xxxxxxxx, A. T., Xxxxx, X., Xxxxx, C.A., 2008. Sexual function in women with Xxxxxx syndrome. J. Womens Health (Larchmt) 17, 27-33. Xxxxxx, P.T., Xxxxxxx, R., Xxxxxxx, B., 1998. The psychological consequences of Xxxxxx syndrome and review of the National Cooperative Growth Study psychological substudy. Pediatrics 102, 488-491. Xxxxx, X.X., Xxxx, X.X., 1966. The anatomy and histology of XO human embryos and fetuses. Anat. Rec. 155, 369-383. Xxxxx, D., Xxxxx, E.E., Xxxxxxxxx, J., 1994. Psychosocial functioning in the Xxxxxx syndrome: A national survey. In: Xxxxxxx B., Xxxxxxxxx L.E. (Eds.), Growth, Stature, and Adaptation. University of North Carolina, Chapel Hill, pp. 151-164. Xxxxxxxxxxx, X.X., 1980. Preliminary manual for the State-Trait Anger Scale (STAS). University of South Florida, Tampa. Xxxxxx, X.X., XxXxxxxx, E., 2004. Xxxxxx’x syndrome. X. Xxxx. J. Med. 351, 1227-1238. Xxxxxx, X.X., Xxxxxxxxxx, X.X., Xxxxxxx, X.X., Xxxxxxxx, X., Xxxxx, X., Xxxxxxxxx, X., 1983. Assessment of skeletal maturity and prediction of adult height (TW2 method). 2nd ed. Academic Press, London, pp. 54-71. Xxxxxxx, X.X., 2005. Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Xxxxxx syndrome. Horm. Res. 63, 238-244. Xxxxxxxx, X.X., xxx xxx Xxxx, J., Xxxx, X.X., 1996. Handleiding voor de CBCL/4-18. Afdeling Kinder- en jeugdpsychiatrie Sophia Kinderziekenhuis/Academisch Ziekenhuis/Erasmus Universiteit, Rotterdam. Xxxxxxxxx-Xxxxx, X., Xxxxxxx-Xxxxxxx, T., Xxxxxxxxx, X., Xxxxx, M., Xxxxxx-Xxxxxx, X., Xxxxxxxx, Z., 2009. Androgen replacement therapy in Xxxxxx syndrome: a pilot study. J. Clin. Endocrinol. Metab. 94, 4820-4827. 138 Chapter 6 Age at starting GH – yr 4.9±1.7 4.8±1.8 5.2±1.6 10.4±1.4 9.3±1.2 9.8±0.8 13.5±1.3 13.5±1.2 13.2±1.3 Height at starting GH – SDS† -2.8±0.7 -2.8±0.8 -2.8±0.7 -2.7±0.8 -2.9±0.5 -2.9±0.6 -3.3±0.6 -3.4±0.7 -3.2±0.9 Age at starting Ox/Pl – yr 8.5±0.3 8.2±0.2 8.3±0.2 10.4±1.4 9.3±1.2 9.8±0.8 13.5±1.3 13.5±1.2 13.2±1.3 Age at starting estrogens or at B2 – yr‡ 11.4±1.4 11.9±0.9 11.6±0.8 12.4±0.7 12.4±0.3 12.2±0.5 13.4±1.3 12.9±0.6 12.6±0.6 Karyotype, 45,X – no. (%)§ 5 (50) 6 (46) 6 (46) 9 (60) 4 (33) 5 (39) 6 (60) 3 (25) 3 (38) Karyotype, other – no. (%)§ 5 (50) 7 (54) 7 (54) 6 (40) 8 (67) 8 (62) 4 (40) 9 (75) 5 (63) Puberty developed spontaneously – no. (%) 4 (40) 2 (15) 6 (46) 4 (27) 4 (33) 2 (15) 1 (10) 2 (17) 1 (13) Duration of GH therapy – yrs 9.9±2.1 9.2±2.4 8.8±1.9 5.0±1.5 5.5±1.2 5.1±1.1 3.8±0.8 3.5±0.7 3.0±0.7...
